Regeneron closes Q3 with 36% revenue growth to $5.12 billion

Regeneron Pharmaceuticals (NASDAQ:REGN) reported third-quarter 2026 revenue of $5.116 billion, up 36% year over year, while GAAP diluted earnings per share increased 35% to $18.45.

Net income increased 33% to $1.949 billion, while revenue from the company's collaboration with Sanofi rose 68% to $2.724 billion compared with the same quarter last year.

The company reported that its expanded alliance with Sanofi includes a $1 billion upfront payment and up to $7 billion in conditional milestone payments.

U.S. EYLEA HD sales increased 62% to $699 million, although combined U.S. EYLEA HD and EYLEA sales declined 1% to $1.099 billion, while global Libtayo sales rose 51% to $550 million.

The expanded Sanofi agreement includes a $1 billion upfront payment expected to be recognized as fourth-quarter collaboration revenue, alongside up to $7 billion in conditional milestones.

Regeneron also received FDA approval for Pasatru for adults with fibrodysplasia ossificans progressiva and raised its 2026 research spending outlook while lowering expected selling and administrative expenses and increasing its expected product gross margin.

Regeneron develops and commercializes medicines for serious diseases across oncology, immunology, cardiovascular, eye and rare disease markets, with major products including EYLEA, Dupixent through its Sanofi collaboration and Libtayo.